TY - JOUR
T1 - Full exploitation of high dimensionality in brain imaging
T2 - The JPND working group statement and findings
AU - Adams, Hieab H.H.
AU - Roshchupkin, Gennady V.
AU - DeCarli, Charles
AU - Franke, Barbara
AU - Grabe, Hans J.
AU - Habes, Mohamad
AU - Jahanshad, Neda
AU - Medland, Sarah E.
AU - Niessen, Wiro
AU - Satizabal, Claudia L.
AU - Schmidt, Reinhold
AU - Seshadri, Sudha
AU - Teumer, Alexander
AU - Thompson, Paul M.
AU - Vernooij, Meike W.
AU - Wittfeld, Katharina
AU - Ikram, M. Arfan
N1 - Funding Information:
B.F. has obtained educational speaking fees from Medice and Shire. H.J.G. has received travel grants and speaker's honoraria from Fresenius Medical Care and Janssen Cilag. He has received research funding from the German Research Foundation (DFG), the German Ministry of Education and Research (BMBF), the DAMP Foundation, Fresenius Medical Care, the EU Joint Programme–Neurodegenerative Disorders (JPND), and the European Social Fund (ESF). W.N. is a founder, shareholder, and scientific lead of Quantib BV. The other authors report no conflicts of interest or financial interests related to this work.Funding was obtained through the Joint Programming in Neurodegenerative Diseases Initiative and the Netherlands Organisation for Health Research and Development (grant number 733051002). B.F. has obtained educational speaking fees from Medice and Shire. H.J.G. has received travel grants and speaker's honoraria from Fresenius Medical Care and Janssen Cilag. He has received research funding from the German Research Foundation (DFG), the German Ministry of Education and Research (BMBF), the DAMP Foundation, Fresenius Medical Care, the EU Joint Programme–Neurodegenerative Disorders (JPND), and the European Social Fund (ESF). W.N. is a founder, shareholder, and scientific lead of Quantib BV. The other authors report no conflicts of interest or financial interests related to this work.
Funding Information:
The Full-HD working group was supported by the international Joint Programme for Neurodegenerative Diseases initiative ( www.neurodegenerationresearch.eu/ ). The aim of the 2016 call was to address harmonization of neuroimaging biomarkers that are relevant for neurodegenerative diseases.
Funding Information:
B.F. has obtained educational speaking fees from Medice and Shire. H.J.G. has received travel grants and speaker's honoraria from Fresenius Medical Care and Janssen Cilag. He has received research funding from the German Research Foundation (DFG), the German Ministry of Education and Research (BMBF), the DAMP Foundation, Fresenius Medical Care , the EU Joint Programme–Neurodegenerative Disorders (JPND), and the European Social Fund (ESF). W.N. is a founder, shareholder, and scientific lead of Quantib BV. The other authors report no conflicts of interest or financial interests related to this work.
Publisher Copyright:
© 2019 The Authors
PY - 2019/12
Y1 - 2019/12
N2 - Advances in technology enable increasing amounts of data collection from individuals for biomedical research. Such technologies, for example, in genetics and medical imaging, have also led to important scientific discoveries about health and disease. The combination of multiple types of high-throughput data for complex analyses, however, has been limited by analytical and logistic resources to handle high-dimensional data sets. In our previous EU Joint Programme–Neurodegenerative Disease Research (JPND) Working Group, called HD-READY, we developed methods that allowed successful combination of omics data with neuroimaging. Still, several issues remained to fully leverage high-dimensional multimodality data. For instance, high-dimensional features, such as voxels and vertices, which are common in neuroimaging, remain difficult to harmonize. In this Full-HD Working Group, we focused on such harmonization of high-dimensional neuroimaging phenotypes in combination with other omics data and how to make the resulting ultra-high-dimensional data easily accessible in neurodegeneration research.
AB - Advances in technology enable increasing amounts of data collection from individuals for biomedical research. Such technologies, for example, in genetics and medical imaging, have also led to important scientific discoveries about health and disease. The combination of multiple types of high-throughput data for complex analyses, however, has been limited by analytical and logistic resources to handle high-dimensional data sets. In our previous EU Joint Programme–Neurodegenerative Disease Research (JPND) Working Group, called HD-READY, we developed methods that allowed successful combination of omics data with neuroimaging. Still, several issues remained to fully leverage high-dimensional multimodality data. For instance, high-dimensional features, such as voxels and vertices, which are common in neuroimaging, remain difficult to harmonize. In this Full-HD Working Group, we focused on such harmonization of high-dimensional neuroimaging phenotypes in combination with other omics data and how to make the resulting ultra-high-dimensional data easily accessible in neurodegeneration research.
KW - Genetics
KW - High-dimensional
KW - Neuroimaging
KW - Omics
KW - Voxel-based morphometry
KW - Voxels
UR - http://www.scopus.com/inward/record.url?scp=85063480768&partnerID=8YFLogxK
U2 - 10.1016/j.dadm.2019.02.003
DO - 10.1016/j.dadm.2019.02.003
M3 - Article
AN - SCOPUS:85063480768
SN - 2352-8729
VL - 11
SP - 286
EP - 290
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
ER -